Prevalence of COVID-19 in Iran: Results of the first survey of the Iranian COVID-19 Serological Surveillance program

Abstract

Background: This study aims to estimate the prevalence of COVID-19 in the general population of Iran. Methods: The target population was all Iranian people aged six years and older in the country. A stratified random sampling design was used to select 28,314 subjects from among the individuals registered in the electronic health record systems used in primary health care in Iran. Venous blood was taken from each participant and tested for the IgG antibody against COVID-19. The prevalence of COVID-19 was estimated at provincial and national levels after adjusting for the measurement error of the laboratory test, non-response bias, and sampling design. Results: Of the 28,314 Iranians selected, 11,256 (39.75%) participated in the study. Of these, 5406 (48.0%) were male, and 6851 (60.9%) lived in urban areas. The mean (standard deviation) participant age was 35.89 (18.61) years. The adjusted prevalence of COVID-19 until August 20, 2020 was estimated as 14.2% (95% uncertainty interval: 13.3%, 15.2%), which was equal to 11,958,346 (95% confidence interval: 11,211,011-12,746,776) individuals. The prevalence of infection was 14.6%, 13.8%, 16.6%, 11.7%, and 19.4% among men, women, urban population, rural population, and individuals 60 years of age and older, respectively. Ardabil, Golestan, and Khuzestan provinces had the highest prevalence, and Alborz, Hormozgan, and Kerman provinces had the lowest. Conclusions: Based on the study results, a large proportion of the Iranian population had not yet been infected by COVID-19. The observance of hygienic principles and social restrictions should therefore continue until the majority of the population has been vaccinated. Keywords: COVID-19, Seroprevalence, Survey, Nationwide, Population-based, Iran, IgG test

The Frequency and Clinical Assessment of COVID-19 in Patients With Chronic Rhinosinusitis

“…Further, a seroepidemiological study carried out on 11 256 Iranian participants reported that the prevalence of COVID-19 (estimated until August 20, 2020) was 14.2%. 13 Moreover, according to the official reports from the Ministry of Health in Iran, by June 20, 2021, 22 321 457 PCR tests were performed, of which 3 086 974 were positive. On the other hand, the positivity rate of SARS-CoV-2 infection was 13.8% in the general population (http://ird.behdasht.gov.ir/).…”

SARS-CoV-2 seroprevalence in asymptomatic or mild symptomatic people and symptomatic patients with negative PCR results: The hidden perspective in epidemiological reports

“…The prevalence proportions of anti_N IgG, anti_S IgG, and anti N and S IgM seropositivity with 95% confidence intervals (CIs) were estimated, adjusting for clustering by location, through cluster robust standard errors (9)(10)(11)(12). The prevalence estimates were adjusted for the test performance i.e., sensitivity (Se) and specificity (Sp) using a Monte Carlo bias analysis with 100,000 samples based on the following formula: TP = (AP + Sp -1) / (Se + Sp -1) where TP denotes true prevalence and AP denotes apparent prevalence (13,14).…”

Inferring the COVID-19 infection fatality rate in the community-dwelling population: a simple Bayesian evidence synthesis of seroprevalence study data and imprecise mortality data

“…There are two countries represented within our data that were identified by Karlinsky and Kobak [57] as having large discrepancies between the official number of deaths attributed to COVID-19 and the number of excess deaths Iran (with UCR=2.4) and Russia (with UCR=4.5). As such, for the Barchuk et al [11] ("Saint Petersburg, Russia") and for the Khalagi et al [58] ("Iran"), we used numbers based on excess deaths (see Supplementary Material for details).…”

“…• For Khalagi et al [58] ("Iran"), Karlinsky and Kobak [57] suggest that official mortality data for Iran is highly inaccurate and suggest that there have been approx. 58,092 excess deaths in Iran for the period until Sept. 21, 2020.…”